Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ENEVO is a **liquid nutrition formula for enteral use**, primarily intended for the maintenance of nutritional health in **postoperative patients**, especially those who require long-term tube feeding or have difficulty with oral intake. It is administered either orally or via feeding tube. One notable component is **phytonadione (vitamin K1)**, with each 250 mL containing 29 μg. Vitamin K1 antagonizes the effect of warfarin, so caution is required when used concomitantly with anticoagulants. ENEVO serves as a balanced source of macro- and micronutrients for patients needing nutritional support and is often used in clinical settings to ensure patients receive adequate caloric and nutritional intake during recovery from surgery or when oral nutrition is inadequate. Adverse reactions such as shock and anaphylaxis have been reported, though the incidence is unknown[1][7][8].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on ENEVO.